2. Search Result
Search Result
Results for "

NSD3

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

1

Recombinant Proteins

1

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-142095
    NSD3-IN-3

    		Histone Methyltransferase Cancer
    NSD3-IN-3 is a potent NSD3 inhibtor with an IC50 value of 1.86 μM. NSD3-IN-3 has anticancer activity and significantly inhibits the growth and proliferation of non-small cell lung cancer cell line H460 .
    NSD3-IN-3
  • HY-155816
    PROTAC NSD3 degrader-1

    		PROTACs Cancer
    PROTAC NSD3 degrader-1 (compound 56) is a PROTAC targeting to Nuclear receptor binding SET domain protein NSD3. PROTAC NSD3 degrader-1 specifically induces NSD3 degradation with DC50 values of 1.43 and 0.94 μM in lung cancer cells NCI-H1703 and A549, respectively. PROTAC NSD3 degrader-1 suppresses the methylation of H3K36, induces apoptosis, and causes cell-cycle arrest. PROTAC NSD3 degrader-1 also downregulates the expression of NSD3-associated genes such as CDC25A, ALDH1A1, and IGFBP.
    PROTAC NSD3 degrader-1
  • HY-155815
    MS9715

    		Histone Methyltransferase PROTACs Cancer
    MS9715 is a potent and seletive NSD3-targeting PROTAC. MS9715 is designed by BI-9321, which binds NSD3’s PWWP1 domain, with an E3 ligase VHL ligand. MS9715 has the potental for NSD3-dependent cancer treatment research .
    MS9715
  • HY-114208A
    BI-9321 trihydrochloride

    		Histone Methyltransferase Cancer
    BI-9321 trihydrochloride is a potent, selective and cellular active nuclear receptor-binding SET domain 3 (NSD3)-PWWP1 domain antagonist with a Kd value of 166 nM. BI-9321 trihydrochloride is inactive against NSD2-PWWP1 and NSD3-PWWP2. BI-9321 trihydrochloride specifically disrupts histone interactions of the NSD3-PWWP1 domain with an IC50 of 1.2 μM in U2OS cells .
    BI-9321 trihydrochloride
  • HY-RS09589
    NSD3 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    NSD3 Human Pre-designed siRNA Set A contains three designed siRNAs for NSD3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    NSD3 Human Pre-designed siRNA Set A
    NSD3 Human Pre-designed siRNA Set A
  • HY-RS17221
    Nsd3 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Nsd3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nsd3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Nsd3 Mouse Pre-designed siRNA Set A
    Nsd3 Mouse Pre-designed siRNA Set A
  • HY-RS23674
    Nsd3 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Nsd3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Nsd3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Nsd3 Rat Pre-designed siRNA Set A
    Nsd3 Rat Pre-designed siRNA Set A
  • HY-142093
    NSD3-IN-1

    		Histone Methyltransferase Cancer
    NSD3-IN-1 (compound B1) is an inhibitor of histone methyltransferase NSD3 with an IC50 value of 28.58 μM .
    NSD3-IN-1
  • HY-142094
    NSD3-IN-2

    		Histone Methyltransferase Cancer
    NSD3-IN-2 is a potent NSD3 inhibitor with an IC50 value of 17.97 μM. NSD3-IN-2 inhibits the growth and proliferation of non-small cell lung cancer cell lines H460, H1299 and H1650 with anti-cancer activity .
    NSD3-IN-2
  • HY-114208
    BI-9321

    		Histone Methyltransferase Cancer
    BI-9321, a chemical probe, is a potent, selective and cellular active nuclear receptor-binding SET domain 3 (NSD3)-PWWP1 domain antagonist with a Kd value of 166 nM. BI-9321 is inactive against NSD2-PWWP1 and NSD3-PWWP2. BI-9321 specifically disrupts histone interactions of the NSD3-PWWP1 domain with an IC50 of 1.2 μM in U2OS cells .
    BI-9321
  • HY-142048
    BI-9466

    		Histone Methyltransferase Cancer
    BI-9466 (Compound 2) is a nuclear receptor-binding SET domain 3 (NSD3)-PWWP1 domain antagonist with a Kd of 144 µM. BI-9466 is a negative control compound of BI-9321 (HY-114208). BI-9466 has no inhibitory activity against NSD3-PWWP1 domain by introduction of a much basic nitrogen heterocycle at the 5-position of BI-9321 .
    BI-9466
  • HY-168920
    NSD-IN-4

    		Histone Methyltransferase Apoptosis Cancer
    NSD-IN-4 (Compound A8) is a potent and an orally active NSD3 inhibitor. NSD-IN-4 induces Apoptosis in a dose-dependent manner. NSD-IN-4 exhibits significant antitumor effects against lung squamous carcinoma .
    NSD-IN-4
  • HY-125244
    LEM-14-1189

    		Histone Methyltransferase Cancer
    LEM-14-1189, a LEM-14 (HY-114340) derivative, is a NSDs inhibitor with IC50s of 418 μM (NSD1), 111 μM (NSD2), and 60 μM (NSD3), respectively. The NSDs, histone lysine methyltransferases (HMTases), are oncoproteins, drivers of a number of tumors. LEM-14-1189 can be used for multiple myeloma (MM) research .
    LEM-14-1189
  • HY-162308
    NSD-IN-3

    		Histone Methyltransferase Apoptosis Cancer
    NSD-IN-3 (compound 3) is a potent nuclear receptor binding SET domain (NSD) inhibitor. NSD-IN-3 inhibits NSD2-SET and NSD3-SET with IC50 values of 0.81 μM and 0.84 μM, respectively. NSD-IN-3 inhibits histone H3K36 dimethylation and decreases the expression of NSDs-targeted genes in non-small cell lung cancer cells. NSD-IN-3 induces s-phase cell cycle arrest and apoptosis .
    NSD-IN-3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: